Moteur de recherche d’entreprises européennes
Financement de l’UE (8 999 813 €) : Développement d’une efficacité vaccinale robuste et innovante Hor01/07/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Développement d’une efficacité vaccinale robuste et innovante
Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others. The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration. To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes. A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable. Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.
| Abbott Biologicals B.V. | 0,00 € |
| Assistance Publique Hopitaux de Paris | 0,00 € |
| Association Internationale de Standardisation Biologique Pour l'Europe(Iabs-EU) | 343 438 € |
| Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana | 3 904 659 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| Institut de Recherche Pour le Developpement | 89 591 € |
| Institut National de la Sante et de la Recherche Medicale | 1 453 491 € |
| Istituto Superiore Di Sanita | 211 048 € |
| Meningitis Research Foundation | 101 456 € |
| Ospedale Pediatrico Bambino Gesu | 321 452 € |
| P95 | 674 315 € |
| Sanofi R&D Vaccins | 0,00 € |
| Seqirus UK Ltd. | 0,00 € |
| Synapse Research Management Partners SL | 393 750 € |
| Terveyden JA Hyvinvoinnin Laitos | 349 250 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 262 972 € |
| Universita Degli Studi Di Firenze | 350 813 € |
| Universite Lyon 1 Claude Bernard | 315 250 € |
| University of Surrey | 228 329 € |
https://cordis.europa.eu/project/id/777363
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.